The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

In June, MSD got FDA approval for a 21-valent vaccine, called Capvaxive, which is the first jab approved for the over-50s category. At the moment, pneumococcal vaccination is recommended for the ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

For individuals reporting past-year cannabis use, decreased odds of opioid misuse observed in states with medical cannabis legalization. (HealthDay News) — For individuals reporting cannabis use ...

Increased cancer incidence seen in digestive, endocrine, oral cavity/pharynx, and respiratory systems between 2016 and 2021. (HealthDay News) — Per- and polyfluoroalkyl substances (PFAS) in ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions. Below is a review of novel drug and biological products ...